Compare PTGX & CAAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | CAAP |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.3B |
| IPO Year | 2016 | 2017 |
| Metric | PTGX | CAAP |
|---|---|---|
| Price | $105.55 | $26.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $108.23 | $26.73 |
| AVG Volume (30 Days) | ★ 713.3K | 254.2K |
| Earning Date | 05-05-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $873.97 | $5.80 |
| Revenue Next Year | N/A | $2.36 |
| P/E Ratio | ★ N/A | $26.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.29 | $17.36 |
| 52 Week High | $107.84 | $30.50 |
| Indicator | PTGX | CAAP |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 49.47 |
| Support Level | $76.63 | $25.07 |
| Resistance Level | $107.84 | $27.26 |
| Average True Range (ATR) | 4.03 | 0.87 |
| MACD | -0.12 | 0.10 |
| Stochastic Oscillator | 84.57 | 52.93 |
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.